Format

Send to

Choose Destination
Proc Natl Acad Sci U S A. 2015 Jan 6;112(1):E21-9. doi: 10.1073/pnas.1417015112. Epub 2014 Dec 18.

Synthetic lethality of combined glutaminase and Hsp90 inhibition in mTORC1-driven tumor cells.

Author information

1
Department of Cell Biology, Harvard Medical School, Boston, MA 02115;
2
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115; and.
3
Department of Cell Biology, Harvard Medical School, Boston, MA 02115; Sandra and Edward Meyer Cancer Center, Department of Pharmacology, Weill Cornell Medical College, New York, NY 10021 jblenis@med.cornell.edu.

Abstract

The mammalian target of rapamycin complex 1 (mTORC1) integrates multiple signals from growth factors, nutrients, and cellular energy status to control a wide range of metabolic processes, including mRNA biogenesis; protein, nucleotide, and lipid synthesis; and autophagy. Deregulation of the mTORC1 pathway is found in cancer as well as genetic disorders such as tuberous sclerosis complex (TSC) and sporadic lymphangioleiomyomatosis. Recent studies have shown that the mTORC1 inhibitor rapamycin and its analogs generally suppress proliferation rather than induce apoptosis. Therefore, it is critical to use alternative strategies to induce death of cells with activated mTORC1. In this study, a small-molecule screen has revealed that the combination of glutaminase (GLS) and heat shock protein 90 (Hsp90) inhibitors selectively triggers death of TSC2-deficient cells. At a mechanistic level, high mTORC1-driven translation rates in TSC1/2-deficient cells, unlike wild-type cells, sensitizes these cells to endoplasmic reticulum (ER) stress. Thus, Hsp90 inhibition drives accumulation of unfolded protein and ER stress. When combining proteotoxic stress with oxidative stress by depletion of the intracellular antioxidant glutathione by GLS inhibition, acute cell death is observed in cells with activated mTORC1 signaling. This study suggests that this combination strategy may have the potential to be developed into a therapeutic use for the treatment of mTORC1-driven tumors.

KEYWORDS:

Hsp90; glutaminase; inhibitors; mTORC1; synthetic lethality

PMID:
25524627
PMCID:
PMC4291663
DOI:
10.1073/pnas.1417015112
[Indexed for MEDLINE]
Free PMC Article

Publication types, MeSH terms, Substances, Grant support

Publication types

MeSH terms

Substances

Grant support

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center